-transparent.png){kind=logo}
Several types of combination therapy, including OK432, cyclophosphamide (CY), and/or lentinan plus bacterial lipopolysaccharide (LPS), reported to have strong antitumor activity against some tumors, were only slightly effective on Lewis lung carcinoma (LC) in C57BL/6 mice. Combination therapy by intralesional injection of OK432 followed by intraperitoneal administration of CY, lentinan and LPS caused almost complete regression of intradermal solid-type LC. Maximal antitumor activity was observed when lentinan and LPS were administered later than CY. Mice in which LC had regressed due to this combination therapy showed an antitumor delayed hypersensitivity reaction (measured by the footpad test), but they were not resistant to rechallenge with LC. These results provide a new model for combination therapy against weakly immunogenic tumors.
S Abe, and
K Takahashi, and
M Yamazaki, and
D Mizuno
January 1986,
Gan to kagaku ryoho. Cancer & chemotherapy,
S Abe, and
K Takahashi, and
M Yamazaki, and
D Mizuno
April 1979,
International journal of cancer,
S Abe, and
K Takahashi, and
M Yamazaki, and
D Mizuno
January 1978,
Proceedings of the Western Pharmacology Society,
S Abe, and
K Takahashi, and
M Yamazaki, and
D Mizuno
May 1979,
Israel journal of medical sciences,
S Abe, and
K Takahashi, and
M Yamazaki, and
D Mizuno
November 1978,
British journal of cancer,
S Abe, and
K Takahashi, and
M Yamazaki, and
D Mizuno
January 1985,
Chemotherapy,
S Abe, and
K Takahashi, and
M Yamazaki, and
D Mizuno
June 2023,
Cancer immunology, immunotherapy : CII,
S Abe, and
K Takahashi, and
M Yamazaki, and
D Mizuno
May 2004,
Bulletin of experimental biology and medicine,
S Abe, and
K Takahashi, and
M Yamazaki, and
D Mizuno
April 2006,
Biochemical and biophysical research communications,
S Abe, and
K Takahashi, and
M Yamazaki, and
D Mizuno
January 1990,
Cancer immunology, immunotherapy : CII,
